Comments
Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan and Hydrochlorothiazide tablets.
The tablets are generic equivalent to Novartis Pharmaceuticals Corp’s Diovan HCT tablets.
The drug is indicated for the treatment of hypertension to lower blood pressure and falls under the cardiovascular (CVS) therapeutic category.
The market size of the product is approximately $1.7 billion for the 12 months ended September 2012, according to IMS.
The product is ready for launch, the Hyderabad-based company said in a release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.